[1] 张伟,陈震宏.晚期结直肠癌靶向治疗进展[J].浙江临床医学,2018,(2):383-385.
[2] 朱胜裕,沈乐荣,叶香华.局部晚期直肠癌新辅助放化疗疗效与血管内皮生长因子水平的关系[J].温州医科大学学报,2018,(1):63-66.
[3] 蔡艳萍,薛顺和.志苓胶囊联合mFOLFOX6方案用于初治老年晚期直肠癌疗效及其安全性观察[J].世界中医药,2017,(10):2343-2346.
[4] hmoll HJ, Stein A. Colorectal cancer in 2013: Towards improved drugs,combinations and patient selection[J]. Nat Rev Clin Oncol, 2014, 11(2): 79-80.
[5] 张志国,李文文,杨凡, 等.SOX联合贝伐单抗和mFOLFOX6联合贝伐单抗方案治疗转移性结直肠癌患者疗效和安全性比较[J].医学综述,2018,(2):389-393.
[6] 崔晓茹,侯勇,于庆生.中医药辅助治疗结直肠癌研究进展[J].安徽中医药大学学报,2017,(2):94-96.
[7] Loupakis F, Cremolini C, Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cance[J]. N Engl J Med, 2014, 371(17): 1609-1618.
[8] Costi R, Leonardi F, Zanoni D, et al. Palliative care and end-stage colorectal cancer manggement: the surgeon meets theoncologist[J]. World J Gastroenterol, 2014, 20(24): 7602-7621. |
2019, Vol. 36 
